Evidence map›Paper›PMID 35496789›Full record

ArticleSTAR protocols2022

An optimized FusX assembly-based technique to introduce mitochondrial TC-to-TT variations in human cell lines.

Bibekananda Kar, Ankit Sabharwal, Santiago Restrepo-Castillo, Brandon W Simone, Karl J Clark, Stephen C Ekker

Abstract read
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bibekananda KarDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Ankit SabharwalDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Santiago Restrepo-CastilloMayo Clinic Graduate School of Biomedical Sciences, Virology and Gene Therapy Track, Mayo Clinic, Rochester, MN, USA.
Brandon W SimoneDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Karl J ClarkDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Stephen C EkkerDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

Funding

Conditional genetics and precision genome editing resources for ZebrafishR24OD036201 · OD · IOWA STATE UNIVERSITY · PI KARL J CLARK, Stephen Carl Ekker · 2024 to 2026
$3.0M
Building the mitochondrial genome editing repertoireU01AI142773 · NIAID · MAYO CLINIC ROCHESTER · PI CLARK, KARL J, EKKER, STEPHEN CARL · 2018 to 2022
$2.0M
NIAID NIH HHS U01 AI142773NIH HHS R24 OD036201
6 · The paper itself

Abstract

The FusX TALE Based Editor (FusXTBE) is a programmable base editing platform that can introduce specific TC-to-TT variations in the mitochondrial DNA (mtDNA). Here, we provide a protocol describing the synthesis and testing of the FusXTBE plasmids in cultured human cell lines. This tool is designed to be easily modified to work in diverse applications where editing of mitochondrial DNA is desired. For complete details on the use and execution of this protocol, please refer to Sabharwal et al. (2021) and Ma et al. (2016).

Indexed as

DNA, MitochondrialMitochondriaCell LineHumansDNA, MitochondrialCell BiologyCRISPRGeneticsMolecular BiologySequencing

Identifiers

PMID35496789
PMCPMC9038556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.